Phase III DAPA-CKD trial of Farxiga shows efficacy in chronic kidney disease.- AstraZeneca

A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that Farxiga (dapagliflozin), from AstraZeneca, on top of standard of care, reduced the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death in patients with chronic kidney disease (CKD), irrespective of the underlying cause of the disease. CKD is a serious, progressive condition defined by decreased kidney function. The main causes of CKD are diabetes (38%), high blood pressure (26%), and glomerulonephritis (kidney inflammation, 16%). In the subgroup analysis, compared to placebo, Farxiga showed a relative risk reduction (RRR) of 37% for patients whose CKD was primarily driven by diabetic kidney disease; (absolute risk reduction [ARR] = ?5.8%), 25% for high blood pressure; (ARR = ?2.2%), 57% for glomerulonephritis; (ARR = ?7.5%), and 42% for CKD of other or unknown causes. (p?interaction for RRR 0.53). Similarly, Farxiga showed a reduction in all-cause mortality, a secondary outcome, compared to placebo, regardless of underlying CKD cause (p-interaction 0.55). The safety and tolerability of Farxiga was consistent with the well-established safety profile of the medicine. The data were presented at the American Society of Nephrology (ASN) Kidney Week Reimagined 2020.